Correcting the ASCO position on phase I clinical trials in cancer
Correcting the ASCO position on phase I clinical trials in cancer
Related Articles
Weight gain in patients with RET aberrant cancers treated with brain penetrant RET selective inhibitors
Recently, the advent of rearranged during transfection (RET)-selective inhibitors has revolutionized the management of RET-altered cancers.1 Whereas genetically altered RET kinases drive oncogenesis, the wild-type…
T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC
Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.
Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies
Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a…
FDA Oks Sotorasib/Panitumumab in KRAS G12C-Mutant Colorectal Cancer
The approval of this combination is supported by data from the phase 3 CodeBreaK 300 study.
T-DXd Plus Pembrolizumab Elicits Responses in IO-Naive HER2-Expressing or -Mutant NSCLC
Trastuzumab deruxtecan plus pembrolizumab showed early efficacy in patients with IO-naive, HER2-expressing or -mutant non–small cell lung cancer.
Critical Recent NCCN Guideline Updates Affect Dozens of Malignancies
Experts detail how recent NCCN guideline changes in dozens of tumor types are affecting their practices, and we gather all the NCCN updates in a…
Artificial Intelligence–Guided Lung Ultrasound by Nonexperts
This multicenter validation study evaluates the ability of artificial intelligence to guide acquisition of diagnostic-quality lung ultrasound images by trained health care professionals.
FDA Approves Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.